PL3140296T3 - Pirolidynowe modulatory gpr40 do leczenia chorób takich jak cukrzyca - Google Patents

Pirolidynowe modulatory gpr40 do leczenia chorób takich jak cukrzyca

Info

Publication number
PL3140296T3
PL3140296T3 PL15723095T PL15723095T PL3140296T3 PL 3140296 T3 PL3140296 T3 PL 3140296T3 PL 15723095 T PL15723095 T PL 15723095T PL 15723095 T PL15723095 T PL 15723095T PL 3140296 T3 PL3140296 T3 PL 3140296T3
Authority
PL
Poland
Prior art keywords
diabetes
diseases
treatment
gpr40 modulators
pyrrolidine
Prior art date
Application number
PL15723095T
Other languages
English (en)
Polish (pl)
Inventor
Elizabeth A. Jurica
Zhenqiu Hong
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3140296T3 publication Critical patent/PL3140296T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15723095T 2014-05-07 2015-05-06 Pirolidynowe modulatory gpr40 do leczenia chorób takich jak cukrzyca PL3140296T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
EP15723095.4A EP3140296B1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (1)

Publication Number Publication Date
PL3140296T3 true PL3140296T3 (pl) 2018-08-31

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15723095T PL3140296T3 (pl) 2014-05-07 2015-05-06 Pirolidynowe modulatory gpr40 do leczenia chorób takich jak cukrzyca

Country Status (33)

Country Link
US (4) US9873679B2 (cg-RX-API-DMAC7.html)
EP (1) EP3140296B1 (cg-RX-API-DMAC7.html)
JP (1) JP6483156B2 (cg-RX-API-DMAC7.html)
KR (1) KR102336370B1 (cg-RX-API-DMAC7.html)
CN (1) CN106458976B (cg-RX-API-DMAC7.html)
AR (1) AR100328A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015256120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024936A2 (cg-RX-API-DMAC7.html)
CA (1) CA2948161C (cg-RX-API-DMAC7.html)
CL (1) CL2016002809A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120340T1 (cg-RX-API-DMAC7.html)
DK (1) DK3140296T3 (cg-RX-API-DMAC7.html)
EA (1) EA033250B1 (cg-RX-API-DMAC7.html)
ES (1) ES2674531T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180641T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039288T2 (cg-RX-API-DMAC7.html)
IL (1) IL248668B (cg-RX-API-DMAC7.html)
MA (1) MA39427B1 (cg-RX-API-DMAC7.html)
MX (1) MX378160B (cg-RX-API-DMAC7.html)
MY (1) MY181959A (cg-RX-API-DMAC7.html)
NZ (1) NZ727146A (cg-RX-API-DMAC7.html)
PE (1) PE20161363A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016502034B1 (cg-RX-API-DMAC7.html)
PL (1) PL3140296T3 (cg-RX-API-DMAC7.html)
PT (1) PT3140296T (cg-RX-API-DMAC7.html)
RS (1) RS57170B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201609170UA (cg-RX-API-DMAC7.html)
SI (1) SI3140296T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800342T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000444A1 (cg-RX-API-DMAC7.html)
TR (1) TR201809633T4 (cg-RX-API-DMAC7.html)
TW (1) TWI659951B (cg-RX-API-DMAC7.html)
WO (1) WO2015171722A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100328A1 (es) * 2014-05-07 2016-09-28 Bristol Myers Squibb Co Moduladores pirrolidina de gpr40
BR112016025188A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
CN110121343B (zh) 2016-09-12 2023-11-03 整体健康 用作gpr120调节剂的双环化合物
EP3604267A4 (en) * 2017-03-31 2020-12-16 Takeda Pharmaceutical Company Limited Aromatic compound
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3217423A1 (en) 2021-06-16 2022-12-22 Jeffrey M. Schkeryantz Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
BR112012007979A2 (pt) * 2009-10-06 2016-03-29 Bristol Myers Squibb Co moduladores de gpr40 de pirrolidina
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
TW201427971A (zh) * 2012-11-16 2014-07-16 必治妥美雅史谷比公司 二氫吡唑gpr40調節劑
CA2891569A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
CN104918935B (zh) 2012-11-16 2017-07-28 百时美施贵宝公司 二氢吡唑gpr40调节剂
BR112015010791A2 (pt) 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 de di-hidropirazol
WO2015171757A1 (en) 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
AR100328A1 (es) * 2014-05-07 2016-09-28 Bristol Myers Squibb Co Moduladores pirrolidina de gpr40
WO2015169728A1 (en) 2014-05-07 2015-11-12 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome

Also Published As

Publication number Publication date
KR20160147049A (ko) 2016-12-21
AU2015256120B2 (en) 2019-03-28
EP3140296A1 (en) 2017-03-15
MA39427B1 (fr) 2018-09-28
ES2674531T3 (es) 2018-07-02
US20150322044A1 (en) 2015-11-12
WO2015171722A1 (en) 2015-11-12
CA2948161C (en) 2020-10-27
IL248668B (en) 2019-09-26
AU2015256120A1 (en) 2016-12-22
CN106458976A (zh) 2017-02-22
DK3140296T3 (en) 2018-07-23
KR102336370B1 (ko) 2021-12-06
MX378160B (es) 2025-03-10
HRP20180641T1 (hr) 2018-06-01
US10717725B2 (en) 2020-07-21
US20200299267A1 (en) 2020-09-24
TR201809633T4 (tr) 2018-07-23
PH12016502034A1 (en) 2017-01-09
EA033250B1 (ru) 2019-09-30
CA2948161A1 (en) 2015-11-12
CY1120340T1 (el) 2019-07-10
PH12016502034B1 (en) 2022-03-23
PT3140296T (pt) 2018-06-27
MX2016013801A (es) 2017-03-09
JP6483156B2 (ja) 2019-03-13
BR112016024936A2 (pt) 2017-08-15
EA201692037A1 (ru) 2017-06-30
CN106458976B (zh) 2020-05-22
SMT201800342T1 (it) 2018-09-13
EP3140296B1 (en) 2018-04-11
JP2017514856A (ja) 2017-06-08
HUE039288T2 (hu) 2018-12-28
RS57170B1 (sr) 2018-07-31
PE20161363A1 (es) 2016-12-17
IL248668A0 (en) 2017-01-31
MA39427A1 (fr) 2017-11-30
AR100328A1 (es) 2016-09-28
US9873679B2 (en) 2018-01-23
TWI659951B (zh) 2019-05-21
NZ727146A (en) 2020-01-31
MY181959A (en) 2021-01-15
TW201625585A (zh) 2016-07-16
US20190112293A1 (en) 2019-04-18
TN2016000444A1 (en) 2018-04-04
SG11201609170UA (en) 2016-12-29
SI3140296T1 (en) 2018-06-29
US20180099949A1 (en) 2018-04-12
CL2016002809A1 (es) 2017-03-24

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
IL248668B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP3212233A4 (en) Combination therapy for treatment of disease
EP3227330A4 (en) Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
ZA201703112B (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
EP3115012A4 (en) Treatment instrument for endoscope
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
SMT202100082T1 (it) Composti eteroarilici per il trattamento di malattie oftalmiche
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
IL270199A (en) Peptides for the treatment of diabetes
IL248670B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
EP3096775A4 (en) Socs mimetics for the treatment of diseases
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
EP3184055A4 (en) Medical treatment instrument
SMT202300015T1 (it) N,n-bis-2-mercaptoetil isoftalammide per il trattamento delle malattie neurodegenerative
PT3166604T (pt) Agentes para o tratamento de doenças infeciosas retrovirais
AU2015904246A0 (en) Treatment of diabetes
AU2016901862A0 (en) Treatment of diabetes
HK1238246A (en) Iminosugars useful for the treatment of viral diseases
HK1238246A1 (en) Iminosugars useful for the treatment of viral diseases